Arrowhead Pharmaceuticals gets green light for first-of-its-kind FCS therapy
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
The trial aims to measure AF burden—the percentage of time patients spend in arrhythmia—as its primary efficacy endpoint
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
The investigational subcutaneous hepcidin mimetic peptide is designed to regulate iron and red blood cell production
WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation
The work will leverage ProBioGen’s CHO.RiGHT expression platform, powered by its proprietary DirectedLuck transposase technology, alongside PsiBot smart automation
SLE remains a life-threatening autoimmune disease, with patients facing an elevated risk of early mortality and long-term organ damage
Mepolizumab is the first and only monthly biologic in China tested for COPD patients with blood eosinophil counts (BEC) as low as 150 cells/µL
Heart failure affects an estimated 64.3 million people worldwide
Subscribe To Our Newsletter & Stay Updated